Gapping up
In reaction to earnings/guidance:
- LITB +42%, TGT +8.8%, LZB +2.6% (also reinstates dividend), SUPN +2.6%, KE +2.1%, LOW +1.3%
M&A news:
- MNTA +69.5% (to be acquired by Johnson and Johnson (JNJ) for $52.50/share)
- HUD +48.9% (receives acquisition proposal for $7.70 per share)
Other news:
- DTIL +10.8% (FDA has granted Fast Track Designation to Precision for PBCAR0191 for the treatment of advanced B-cell precursor acute lymphoblastic leukemia
- AXDX +9.5% (receives FDA EUA for COVID-19 antibody testing system)
- ONE +8.8% (extends momentum from +29% move during Tuesday's regular session)
- CNTG +6.1% (expands its SARS-CoV-2 testing solution to Hamburg Airport)
- MRCY +5.5% (receives new patent for cyberattack protection technology)
- VRNA +4.9% (initiates multiple dose part of Phase 2 clinical trial with pMDI formulation of Ensifentrine)
- WATT +4.3% (announced a strategic partnership with Xentris Wireless to develop ruggedized products for demanding military applications using Energous' radio frequency (RF) based charging technology)
- IRTC +2.6% (prices offering of 1,093,167 shares of its common stock at $175.00 per share (stock closed at $175.38))
- REGN +1.7% (Regeneron Pharma and Roche's Genentech to collaborate to increase global supply of REGN-COV2)
- UAL +1.3% (will increase service to China from two to four weekly flights)
- MYL +1.3% (FDA approves Mylan's generic version of BIIB's Tecfidera)
- QGEN +1% (expands coronavirus NGS and software to accelerate research for COVID-19)
- NMRD +1% (issued a presentation outlining how CGM is being used by quarantined and hospitalised COVID-19 patients)
Analyst comments:
- RFP +4.6% (upgraded to Outperform from Sector Perform at RBC Capital Mkts)
- XPO +3.1% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- PFPT +2.5% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- GGB +1.7% (upgraded to Overweight from Neutral at JP Morgan)